{"id":307479,"date":"2026-10-14T12:15:28","date_gmt":"2026-10-14T06:45:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=307479"},"modified":"2026-10-14T12:15:28","modified_gmt":"2026-10-14T06:45:28","slug":"contract-manufacturer-emerging-market-generic-and-device-stocks-roadmap-leaders-roundup","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/contract-manufacturer-emerging-market-generic-and-device-stocks-roadmap-leaders-roundup\/","title":{"rendered":"3 Contract Manufacturer, Emerging Market Generic and Device Stocks With a Strong Future Roadmap: Akums Drugs and Pharmaceuticals, Lincoln Pharmaceuticals and Poly Medicure"},"content":{"rendered":"

Akums Rs 769.30, P\/E 42.26. Lincoln Pharma Rs 548.70, P\/E 11.64. Poly Medicure Rs 1,600.00, P\/E 51.87. Closing prices of 13 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Contract manufacturer, emerging market generic and device stocks with the clearest long-term roadmaps today include Akums in contract development and manufacturing of pharmaceutical and nutraceutical products, Lincoln Pharma in formulations sold in India and emerging export markets and Poly Medicure in medical devices such as infusion sets, needles, catheters and dialysis products. FY26 revenue growth was 7.6% at Akums, 9.1% at Lincoln Pharma and 13.4% at Poly Medicure. P\/E stands at 42.26 for Akums (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 51.87 for Poly Medicure (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Contract manufacturer, emerging market generic and device stocks give investors exposure to manufacturing, medicines and devices that drug brands, doctors and hospitals use. Contract orders, export volumes and device sales decide how much of that demand turns into profit.<\/p>\n

This list covers three contract manufacturer, emerging market generic and device stocks: Akums Drugs and Pharmaceuticals for contract development and manufacturing of pharmaceutical and nutraceutical products, Lincoln Pharmaceuticals for formulations sold in India and emerging export markets and Poly Medicure for medical devices such as infusion sets, needles, catheters and dialysis products. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n